ImmuPharma PLC

• 

  20/04/12

  ImmuPharma in broker spotlight after bid emerges for rival lupus drug maker

  GlaxoSmithKline’s $2.6 billion hostile bid for Human Genome Science yesterday highlighted the commercial potential for biotech ImmuPharma's rival lupus drug, Lupuzor, suggest analysts.

• 

  27/03/12

  ImmuPharma in talks with a "number of companies" over Lupuzor

  Drug discovery specialist ImmuPharma this morning said it is in discussions with a “number of companies” interested in jointly developing its breakthrough drug Lupuzor.

• 

  28/02/12

  ImmuPharma: A second bite at the cherry, but is the market really plugged into Lupuzor's potential?

  Very rarely does a small drug company have the opportunity to do the same transaction twice – with every prospect of getting an even better deal the second time around. But this is exactly what has happened with ImmuPharma.

• 

  03/02/12

  Something for everyone at next Thursday's Proactive Investors One2One Forum in London: ImmuPharma, O

  We have a line-up that offers something for everyone at the Proactive Investors One2One Forum in London next Thursday (February 9). We have ImmuPharma and Oxford Pharmascience presenting alongside Seeing Machines and Probability.

• 

  21/11/11

  ImmuPharma's Lupuzor offers "blockbuster sales potential", says Merchant Securities

  Merchant Securities today initiated coverage of ImmuPharma with a ‘buy’ recommendation and 323 pence share price target. The valuation is based mainly on the potential of the company’s Lupuzor treatment for the auto-immune disease lupus, which has been given the regulatory green light to go into phase III clinical trials.

• 

  15/11/11

  ImmuPharma's Lupuzor offers "meaningful market opportunity", says Espirito Santo; shares worth 200p

  Investment Bank Espirito Santo has given a bullish assessment of the prospects for ImmuPharma and its lead drug Lupuzor as it has come up with a 200 pence valuation for the shares.

• 

  03/11/11

  ImmuPharma chief Dimitriou is very optimistic about Lupuzor future

  ImmuPharma chief executive Dimitri Dimitriou said he is very “optimistic about the future” as the company looks to seal a new licensing deal for Lupuzor, its flagship product. He revealed the group had “rekindled discussions” with big pharmaceuticals companies, and he is hopeful a deal can be struck.

• 

  03/11/11

  ImmuPharma says Lupuzor will move into phase III trials with Special Protocol Assessment

  Any lingering doubts over Immupharma’s lead drug, Lupuzor, were dispelled this morning when the group announced it would enter phase III clinical trials.

• 

  21/10/11

  ImmuPharma: regaining of Lupuzor rights to bring “a lot more cash into the company”

  The drug discovery firm’s chief executive expects more interest from big pharma in its Lupus drug candidate now than when it signed its original deal with Cephalon in 2008

• 

  21/10/11

  ImmuPharma will not have to fund Lupuzor Phase III trial, says Merchant

  The broker says that ImmuPharma partner Cephalon has a “moral obligation” in the eyes of the US Food and Drug Administration to complete the clinical trial of the Lupus drug candidate 

• 

  30/09/11

  ImmuPharma comments on Cephalon tie-up provide re-assurance

  It was not quite the rock solid re-assurance followers were expecting. But at least it gave some cause for optimism. ImmuPharma said this morning it will update on the progress of the pivotal study on lead product Lupuzor once the acquisition of partner Cephalon is completed.

• 

  15/07/11

  Immupharma keeps watch on Teva-Cephalon deal

  Immupharma will have been watching Teva Pharmaceuticals’ friendly US$6.8bn bid for Cephalon with great interest considering its development tie-up with Cephalon for Lupuzor, a treatment for auto-immune disease. Cephalon’s expected takeover opens up some interesting pathways for Lupuzor, according to analysts.

• 

  03/05/11

  Investors and analysts react positively to Teva bid for ImmuPharma partner

  ImmuPharma shares were in demand this morning as the future of partner Cephalon became a little clearer.

• 

  06/04/11

  ImmuPharma chief relaxed, confident and upbeat on the prospects for Lupuzor

  The company appears remarkably relaxed about the future of its lead drug, Lupuzor, despite some near-term uncertainty.

• 

  05/04/11

  ImmuPharma's Warr "confident of the potential" of lead drug Lupuzor

  ImmuPharma said this morning lead drug Lupuzor has a strong future despite uncertainty over the future of development partner Cephalon, which is the focus of a US$5.7 billion hostile bid. Chairman Richard Warr said this morning he is confident of the potential of the drug “irrespective of recent developments surrounding our licensing partner”.

   

• 

  30/03/11

  Bang goes the theory as Valeant bids for ImmuPharma partner Cephalon

  US drugs group Cephalon was seen the potential buyer of AIM-listed ImmuPharma. Now the predator has become the prey. with Valeant Pharma launching a $5.7 billion takeover tilt for Cephalon. We examine the fall-out and ramifications of the Valeant deal for ImmuPharma.  

• 

  25/03/11

  Might Cephalon be ready to pounce on ImmuPharma?

  Panmure Gordon's Savvas Neophytou is pondering whether ImmuPharma's US partner Cephalon might be thinking of acquiring the UK drugs discovery group before potentially positive results from a pivotal clinical study make ImmuPharma's low valuation a thing of the past and trigger large milestones and royalties.

• 

  11/03/11

  Benlysta approval positive for ImmuPharma, says Matrix analyst Malik

  The market has been slow to react to a US Food & Drugs Administration approval which could have some very positive implications for AIM-listed ImmuPharma (LON:IMM). This week lupus drug Benlysta was given the green light by the FDA with a clean label. The tiny AIM-listed biotechnology firm has a potentially more efficacious drug candidate.

   

• 

  21/02/11

  A muted response to ImmuPharma cancer update, yet there are plenty of reasons to be hopeful

  The market today gave a muted response to some very encouraging early stage data on a fledgling cancer drug being developed by ImmuPharma. The drug is in the formative stages of development, which means analysts aren't ready to ascribe a valuation to the potentially breakthrough treatment. That said, the analysts already have some pretty punchy valuations for ImmuPharma based on its other drug, Lupuzor, for auto-immune disease Lupus.

• 

  27/01/11

  Immupharma: City analyst sees opportunity ahead of crucial trial results

  The AIM-listed drug company is developing a treatment for Lupus, a life threatening auto-immune disease, which could take a prominent place in a multi-billion dollar market. Immupharma shares have had a bumpy ride of late but Panmure Gordon analyst Savvas Neophytou reckons the recent weakness presents an opportunity for new investors ahead of potentially transformational clinical trial results later this year.

   

• 

  12/10/10

  ImmuPharma has the cash and prospects to be one of the sector's big winners

  We take a closer look at ImmuPharma, a biotechnology company with plenty of cash and lead drug candidate that has blockbuster potential.

• 

  08/04/10

  ImmuPharma voted Best Drug Development Company in Europe

  ImmuPharma’s internal focus (Lupuzor is now the responsibility of Cephalon) remains on the progression of its lead drug candidates, particularly its cancer compound, IPP-204106.

• 

  19/10/09

  Abcam, Immupharma, Vertu Motors, Asian Citrus, Max Property Group, Research Now, May Gurney Integrat

  The annual AIM award occurred last Thursday, inside is a list of the companies nominated in each of the categories, and the winners.

Connect with Facebook to view or add comments for this company